TBPH
Theravance·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
TBPH fundamentals
Theravance (TBPH) released its earnings on Nov 10, 2025: revenue was 19.99M (YoY +18.51%), beat estimates; EPS was 0.07 (YoY +216.67%), beat estimates.
Revenue / YoY
19.99M
+18.51%
EPS / YoY
0.07
+216.67%
Report date
Nov 10, 2025
TBPH Earnings Call Summary for Q3,2025
- YUPELRI Record Performance: Q3 net sales $71.4M (15% YoY), hospital share at 21%, and $25M milestone on track with $54M needed in Q4.
- CYPRESS Trial Catalyst: Q1 2026 readout for ampreloxetine in MSA-related nOH, with $75M Q4 milestones and $100M 2026 TRELEGY target.
- Financial Strength: $333M cash, non-GAAP breakeven, and clinical data supporting long-term value.
- Strategic Focus: Execution on CYPRESS and YUPELRI growth, with potential capital return post-data.
EPS
Revenue
Revenue & Expenses
TBPH has released its 2025 Q3 earnings report, with revenue of 19.99M, reflecting a YoY change of 18.51%, and net profit of 3.62M, showing a YoY change of 128.47%. The Sankey diagram below clearly presents TBPH's revenue sources and cost distribution.
Key Indicators
Theravance (TBPH) key financial stats and ratios, covering profitability, financial health, and leverage.
Theravance (TBPH)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.
Trend
Breakdown
Theravance (TBPH)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.
Trend
Breakdown
Theravance (TBPH)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.
Trend
Breakdown
Where does Theravance (TBPH) generate its revenue? Explore its key revenue streams and top earning regions.
By Business
Data source:
By Region
Data source:
Track Theravance (TBPH) Dividend Yield, Payout Ratio & Sustainability Through Its Dividend History
Payout Ratio
Dividend Yield
You can ask Aime
What were the key takeaways from Theravance's earnings call?What is the revenue and EPS growth rate for Theravance year over year?What does Theravance do and what are its main business segments?What guidance did Theravance's management provide for the next earnings period?What factors drove the changes in Theravance's revenue and profit?What were the key takeaways from Theravance’s earnings call?Did Theravance beat or miss consensus estimates last quarter?What is Theravance's latest dividend and current dividend yield?
